Aclarion Inc
NASDAQ:ACON
Aclarion Inc
Research & Development
Aclarion Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aclarion Inc
NASDAQ:ACON
|
Research & Development
-$888.8k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Research & Development
-$750.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-29%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Research & Development
-$103.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Research & Development
-$93m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Research & Development
-$88.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Research & Development
-$54.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aclarion Inc
Glance View
Aclarion Inc is a US-based company operating in Health Care Technology industry. The company is headquartered in San Mateo, California. The company went IPO on 2022-04-22. Aclarion, Inc. is a healthcare technology company that employs magnetic resonance spectroscopy (MRS) and artificial intelligence (AI) technology to optimize clinical treatments. The Company’s technology is focused on improving surgical decision making when surgical intervention is being contemplated for patients with low back pain. Its first commercial product, NOCISCAN-LS, utilizes its proprietary biomarkers and algorithms to provide surgeons with information about which intervertebral discs are determined to be consistent with generating pain, and which are not. NOCISCAN is a software as a service (SaaS) platform to leverage MRS to non-invasively help physicians distinguish between painful and nonpainful discs in the spine. The platform used to conduct a NOCISCAN-LS involves NOCISCAN-LS MRS exam protocol, data transfer, and the NOCISCAN-LS post-processor suite. The Company’s NOCISCAN-LS post processor suite is comprised of two software products, such as NOCICALC-LS and NOCIGRAM.
See Also
What is Aclarion Inc's Research & Development?
Research & Development
-888.8k
USD
Based on the financial report for Dec 31, 2024, Aclarion Inc's Research & Development amounts to -888.8k USD.
What is Aclarion Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-4%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Aclarion Inc have been -4% over the past three years .
